# A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients

> **NCT02017717** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 529 (actual)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Bevacizumab
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT02017717
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-07
- **Primary completion:** 2019-06-17
- **Final completion:** 2024-06-21
- **Target enrollment:** 529 (ACTUAL)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02017717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02017717, "A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02017717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*